TOYOPEARL AF-rProtein A Antibody Affinity Purification
TOYOPEARL AF-rProtein A HC-650F is designed for high capacity purification of antibodies
Receive your quote directly from the manufacturer.
Good results, but not purchased in production.
mAb purification
It's easy to use. We compared with the commonly used protA resins, and it's quite good.
Review Date: 19 Mar 2021 | Tosoh Bioscience - Separations
Very useful for some of our applications.
Antibody purification
Fast equibrilation and low unspecific binding compared to different other providers.
Review Date: 7 Feb 2020 | Tosoh Bioscience - Separations
TOYOPEARL AF-rProtein A HC-650F is designed for high capacity purification of antibodies
TOYOPEARL AF-rProtein A HC-650F allows to increase productivity and to reduce production costs: It excels over other commercially available Protein A media. IgG DBCs over 100 g/L can even be observed at higher titers. This prevents DSP bottlenecks even at short resi¬dence times. Improved mass transfer characteristics allow it to maintain a larger percent of its capacity at lower residence times relative to agarose based, caustic stable resins.
Its alkali stability allows at least 300 Cleaning-in-Place (CIP) cycles (at 0.2 M NaOH) without significant reduction in dynamic binding capacity.
Protein A resins constitute a substantial cost in state-of-the-art mAb purification processes. Factors such as operating cycles, capacity, and mAb titer can have an impact on total costs associated with mAb purification. The high capacity of the new TOYOPEARL AF-rProtein A HC-650F resin and its high alkaline resistance increase product throughput, reduce operating costs and increase manufacturing productivity.
Purification of biomolecules with chromatography techniques
Bioprocess chromatography is an effective purification technique and is key for the successful development and commercialization of new drugs, no matter whether biologic, biosimilar, or biobetter. Explore over twenty application notes covering aspects of biopharmaceutical purification such as capturing of antibody constructs, mAb aggregate removal using salt-tolerant IEC or hydroxyapatite, intermediate purification of bi-specific antibodies with a non-affinity platform using MXC and HIC, antibody-drug conjugates (ADC) purification on HIC resin, or separation of oligonucleotides on highly-selective anion exchanger.
